Impact of cannabis use and cannabis composition on formal thought disorder and related brain networks: An fMRI study in 51 patients with schizophrenia.
Thomas Bernabeu, Mathilde Argote, Antony Citterio-Quentin, Natalie Giloux, Guillaume Sescousse, Benjamin Rolland
{"title":"Impact of cannabis use and cannabis composition on formal thought disorder and related brain networks: An fMRI study in 51 patients with schizophrenia.","authors":"Thomas Bernabeu, Mathilde Argote, Antony Citterio-Quentin, Natalie Giloux, Guillaume Sescousse, Benjamin Rolland","doi":"10.1016/j.schres.2026.10.013","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Formal thought disorder (FTD) is a core dimension of schizophrenia, which has been associated in previous studies with increased brain functional connectivity between temporal gyri and striatal regions as measured with fMRI. Cannabis use is highly prevalent in schizophrenia population as compared with the general population and, in the context of elevated tetrahydrocannabinol/cannabidiol (THC/CBD) ratio, has been found to be associated with increased FTD in schizophrenia. Consequently, in this study, we aimed to investigate whether cannabis consumption in patients with schizophrenia is generally associated with both enhanced functional connectivity and FTD.</p><p><strong>Methods: </strong>We explored the functional connectivity between the temporal gyri and striatal regions in 51 schizophrenia patients divided into two groups stratified by cannabis use. FTD was measured using the conceptual disorganization item from the Positive And Negative Syndrome Scale. Region-of-interest (ROI)-to-ROI and seed-based connectivity analyses, correlation tests, and mediation models were conducted using both frequentist and Bayesian approaches.</p><p><strong>Results: </strong>No significant difference was found in terms of functional connectivity between cannabis users and non-users. THC/CBD ratio was not significantly associated with cortico-striatal connectivity or FTD. Overall, Bayesian results indicated moderate to strong evidence favoring the null hypothesis across most models.</p><p><strong>Conclusion: </strong>Cannabis use was not robustly associated with an altered cortico-striatal connectivity in this sample. The convergence of frequentist and Bayesian evidence suggests that cannabis use may not account for previously reported FTD-related connectivity alterations in schizophrenia. Larger studies considering cannabis composition, dose-response relationships, and symptom dimensions are warranted to refine these findings.</p>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":"298 ","pages":"285-292"},"PeriodicalIF":3.7000,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.schres.2026.10.013","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Formal thought disorder (FTD) is a core dimension of schizophrenia, which has been associated in previous studies with increased brain functional connectivity between temporal gyri and striatal regions as measured with fMRI. Cannabis use is highly prevalent in schizophrenia population as compared with the general population and, in the context of elevated tetrahydrocannabinol/cannabidiol (THC/CBD) ratio, has been found to be associated with increased FTD in schizophrenia. Consequently, in this study, we aimed to investigate whether cannabis consumption in patients with schizophrenia is generally associated with both enhanced functional connectivity and FTD.
Methods: We explored the functional connectivity between the temporal gyri and striatal regions in 51 schizophrenia patients divided into two groups stratified by cannabis use. FTD was measured using the conceptual disorganization item from the Positive And Negative Syndrome Scale. Region-of-interest (ROI)-to-ROI and seed-based connectivity analyses, correlation tests, and mediation models were conducted using both frequentist and Bayesian approaches.
Results: No significant difference was found in terms of functional connectivity between cannabis users and non-users. THC/CBD ratio was not significantly associated with cortico-striatal connectivity or FTD. Overall, Bayesian results indicated moderate to strong evidence favoring the null hypothesis across most models.
Conclusion: Cannabis use was not robustly associated with an altered cortico-striatal connectivity in this sample. The convergence of frequentist and Bayesian evidence suggests that cannabis use may not account for previously reported FTD-related connectivity alterations in schizophrenia. Larger studies considering cannabis composition, dose-response relationships, and symptom dimensions are warranted to refine these findings.
期刊介绍:
As official journal of the Schizophrenia International Research Society (SIRS) Schizophrenia Research is THE journal of choice for international researchers and clinicians to share their work with the global schizophrenia research community. More than 6000 institutes have online or print (or both) access to this journal - the largest specialist journal in the field, with the largest readership!
Schizophrenia Research''s time to first decision is as fast as 6 weeks and its publishing speed is as fast as 4 weeks until online publication (corrected proof/Article in Press) after acceptance and 14 weeks from acceptance until publication in a printed issue.
The journal publishes novel papers that really contribute to understanding the biology and treatment of schizophrenic disorders; Schizophrenia Research brings together biological, clinical and psychological research in order to stimulate the synthesis of findings from all disciplines involved in improving patient outcomes in schizophrenia.